SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-030323
Filing Date
2023-04-17
Accepted
2023-04-17 17:19:05
Documents
14
Period of Report
2023-04-17
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea177029-8k_nektar.htm   iXBRL 8-K 35145
2 PRESS RELEASE TITLED "NEKTAR THERAPEUTICS ANNOUNCES STRATEGIC REPRIORITIZATION A ea177029ex99-1_nektar.htm EX-99.1 30069
3 GRAPHIC ex99-1_001.jpg GRAPHIC 2044
  Complete submission text file 0001213900-23-030323.txt   252569

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nktr-20230417.xsd EX-101.SCH 3221
5 XBRL LABEL FILE nktr-20230417_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE nktr-20230417_pre.xml EX-101.PRE 22355
8 EXTRACTED XBRL INSTANCE DOCUMENT ea177029-8k_nektar_htm.xml XML 3489
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

IRS No.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 23824786
SIC: 2834 Pharmaceutical Preparations